Format

Send to

Choose Destination
J Antimicrob Chemother. 2012 Jan;67(1):167-9. doi: 10.1093/jac/dkr403. Epub 2011 Sep 27.

In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci.

Author information

1
Servicio de Microbiología Clínica, Hospital Clínico San Carlos, Plaza Cristo Rey s/n, 28040 Madrid, Spain. irodriguezi.hcsc@salud.madrid.org

Abstract

OBJECTIVES:

To compare the activity of tedizolid (formally known as torezolid and TR-700) with that of 15 agents against a collection of linezolid-resistant staphylococci (164 coagulase-negative staphylococci and 5 Staphylococcus aureus).

METHODS:

Antimicrobial susceptibility tests were performed using the broth microdilution method following the recommendations of the CLSI.

RESULTS:

All isolates were susceptible to vancomycin and tigecycline. Based on the MIC(90) values, the potency of tedizolid against coagulase-negative staphylococci was >16-fold greater than that of linezolid. Tedizolid retained activity against most of the linezolid-resistant staphylococci tested, including multidrug-resistant isolates with elevated linezolid MICs (32 to >128 mg/L). Of the isolates, 79.2% and 31.4% were inhibited by tedizolid at ≤ 4 mg/L and ≤ 2 mg/L, respectively.

CONCLUSIONS:

The results of this study confirm the activity of tedizolid against linezolid-resistant staphylococci. This new oxazolidinone could have an important role as a potential therapeutic agent against multidrug-resistant staphylococci.

PMID:
21954458
DOI:
10.1093/jac/dkr403
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center